Mesoblast (MESO) has released an update.
Mesoblast Limited, a leader in cellular medicines, has announced a convertible note subscription agreement with its major shareholder for up to $50 million to support the potential launch of its lead product candidate, RYONCIL, pending FDA approval. The funding aims to ensure a smooth commercial rollout for the treatment of children with steroid-refractory acute graft versus host disease. The agreement includes the option for the investor to convert the notes into shares, with the arrangement aiding Mesoblast in strengthening its market strategy and securing financial stability ahead of the FDA’s decision.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.
